Breast Tumour Size Measurement by Field Cycling Imaging
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorUniversity of Aberdeen
About this trial
The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately estimate tumour size in patients with a type of breast cancer called ductal carcinoma in situ (DCIS). The main question it aims to answer is:
Can FCI accurately estimate DCIS lesion size compared with histology results?
Participants will have a standard MRI scan and an FCI scan before undergoing surgery to remove the tumour.
Eligibility criteria
Qualifiers
Females ≥ 18 years old.
Subjects diagnosed with DCIS on initial biopsy.
Lesion size >1 cm on imaging.
Subjects undergoing surgery as part of their treatment.
Disqualifiers
Subjects undergoing chemotherapy or hormonal therapy.
Individuals unable to give informed consent.
Contra-indications to MRI scanning such as implantable cardiac devices.
Known allergy to contrast agent.
Trial design
Treatments tested in this trial
- Field-Cycling Imaging research scan
- 3T MRI research scan
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Aberdeen
Lead sponsor
NHS Grampian
Collaborator
Source ClinicalTrials.gov